Filing identity and reporting period
Important discrepancy: The supplied filing text is for IsoRay, Inc., not Perspective Therapeutics, Inc. It is a Form 10-Q for the quarter ended March 31, 2016 (IsoRay’s fiscal third quarter), filed May 10, 2016. The summary below reflects the filing text provided.
IsoRay manufactures and sells Proxcelan Cesium-131 brachytherapy seeds. The filing reports results for the three and nine months ended March 31, 2016, compared with the same periods in 2015.
Key financial results
| Metric | Three months ended March 31, 2016 | Three months ended March 31, 2015 | Nine months ended March 31, 2016 | Nine months ended March 31, 2015 |
|---|---|---|---|---|
| Product sales | $1.199 million | $1.158 million | $3.649 million | $3.266 million |
| Gross profit (loss) | $66,304 | $55,197 | $176,674 | $(37,569) |
| Gross margin | 5.5% | 4.8% | 4.8% | (1.2%) |
| Operating expenses | $1.393 million | $1.106 million | $4.005 million | $3.195 million |
| Operating loss | $(1.327) million | $(1.051) million | $(3.828) million | $(3.232) million |
| Net loss | $(1.195) million | $(954,000) | $(3.526) million | $(2.646) million |
| Basic and diluted loss per share | $(0.02) | $(0.02) | $(0.06) | $(0.05) |
For the nine months ended March 31, 2016, operating cash use was $2.676 million, compared with $2.892 million in the prior-year period. Investing activities provided $3.104 million, primarily reflecting net certificate-of-deposit maturities and purchases; financing activities provided $39,308. Cash and cash equivalents increased $468,000 to $5.694 million.
At March 31, 2016, cash, cash equivalents and certificates of deposit totaled $16.797 million, including $5.192 million in non-current certificates of deposit. Current assets were $13.240 million and current liabilities were $1.212 million. Total liabilities were $2.271 million, including a $1.014 million asset retirement obligation and a $45,000 warrant derivative liability. The filing reports no interest-bearing borrowings.
Changes and operating developments
- Third-quarter sales increased 4% year over year; nine-month sales increased 12%, primarily from more brachytherapy seed treatments.
- Gross profit improved in both periods, including a move from a nine-month gross loss to gross profit, but gross margins remained low.
- Net loss widened 25% for the quarter and 33% for the nine-month period. Higher general and administrative costs were the primary driver; nine-month G&A rose 63%, including CEO transition/severance costs, legal expense, and stock-based compensation.
- Sales and marketing expense declined 20% for the quarter and 19% for the nine months, partly because positions were vacant. Senior marketing and sales leadership positions were filled in February and March 2016, and a territory manager vacancy was filled in April.
- Other brachytherapy applications contributed about 12% of revenue in both the quarter and nine-month period. Management reported year-over-year growth in these applications, while noting that demand is variable and depends on a small number of physicians.
- The company discontinued the GliaSite RTS product line and recorded a $72,200 related inventory write-off. Management said it had provided notice of termination of related agreements in April 2016.
- IsoRay purchased adjacent land for a planned production facility and began design work. The development covenants include construction deadlines, facility-use and employment requirements; noncompliance could require an estimated payment of about $256,000, subject to changes in land value.
Outlook, risks and contingencies
- Management stated that cash and investments held at May 6, 2016 were expected to fund anticipated needs for the next three years, assuming revenue and expenses remained at current levels. This is an assumption-based estimate, not a guarantee.
- Management’s stated objectives were to pursue breakeven through growth in prostate and other cancer applications while controlling costs. The filing provides no specific revenue or earnings guidance and cautions that profitability and revenue growth are not assured.
- Management expected monthly cash operating expenses to increase over historical levels as vacant positions were filled and outside marketing and reimbursement expertise was engaged. Construction costs for the new facility were not yet established.
- Product and reimbursement risks include dependence on Proxcelan as the sole revenue product after GliaSite discontinuation, physician adoption, clinical evidence, payer reimbursement and competition from other treatments. For some non-prostate procedures, seeds implanted during surgery are not separately reimbursed under Medicare.
- Customer concentration is material: the risk-factor disclosure says approximately 51% of revenue depends on five customers, and one customer group represented 22% of accounts receivable at March 31, 2016. The filing also notes that one customer accounted for at least 10% of nine-month revenue, without specifying its exact percentage there.
- A Russian isotope supplier experienced an unplanned disruption during the quarter ended December 31, 2015. No customer orders were missed or delayed, but management planned to test and update its supply-interruption plan over the following nine to twelve months. The company also relies on some single-source component suppliers.
- A securities class action related to a May 2015 press release remained pending. IsoRay said it believed the case was without merit and sought dismissal; the motion hearing was scheduled for May 12, 2016. The filing does not provide a clear estimate of potential loss.
- A dispute with the Lawrence Family Trust over a know-how royalty license remained unresolved; the parties could demand binding arbitration. Management believed no royalty was due and did not intend to use the know-how.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter.
Most important facts to verify
- Confirm the intended issuer and filing: the provided document identifies IsoRay, Inc., not Perspective Therapeutics, Inc.
- Verify current liquidity, certificate-of-deposit maturities, operating cash burn and the assumptions behind management’s three-year funding estimate.
- Track sales growth against persistently low gross margins and the company’s path toward breakeven.
- Review customer concentration, receivable collections, reimbursement exposure and supply continuity for Cesium-131 and other components.
- Monitor the securities litigation, know-how royalty dispute, and the costs and covenant deadlines associated with the planned facility.
- Assess the effects of GliaSite discontinuation and the transition to reliance on Proxcelan as the sole revenue product.